News report 📈 Stocks 🌍 United States

Rafael Holdings Faces Pomerantz Investigation Following Failed Phase 3 Trial

Rafael Holdings is under scrutiny by Pomerantz LLP after its Phase 3 TransportNPC study missed primary endpoints, causing a 34.98% stock price collapse to $1.32.

🕐 1 min read

1 assets impacted (Stocks). Net bias: 0 Bullish, 1 Bearish, 0 Neutral. Strongest signal: RFL ↓ 3/10 (60% confidence).

📊 Affected Assets (1)

RFL
Bearish 🤖 60%
📅 Short-term 🌍 US · Explicit

Pomerantz is investigating securities-fraud claims against Rafael and its officers after the September 30, 2026 announcement that the Phase 3 TransportNPC study missed statistical significance, a day the stock already collapsed 34.98% to $1.32. The fresh investigation adds legal overhang and selling pressure, though the large price damage already occurred and investigations alone are routine events.

Catalysts
  • ▼ Pomerantz LLP investor investigation announced November 5, 2026
  • ▼ Failed primary endpoint in the Phase 3 TransportNPC study disclosed September 30, 2026
Risk Factors
  • ▲ The 34.98% price drop already occurred on September 30, so the negative trial result is largely priced in
  • ▲ An investigation is not a filed lawsuit, and outcomes for the company are uncertain
▼ Show FAQ (2) ▲ Hide FAQ
Why is Rafael Holdings under investigation?

The law firm Pomerantz is looking into whether Rafael and certain officers or directors engaged in securities fraud, after the company's September 30, 2026 press release said its Phase 3 TransportNPC study did not achieve statistical significance on the primary endpoint.

How much did the stock fall on the bad trial news?

The stock fell $0.71 per share, or 34.98%, to close at $1.32 per share on September 30, 2026.

🎯 Key Takeaways

  • Pomerantz LLP is investigating potential securities fraud by Rafael Holdings officers and directors.
  • The investigation stems from the failure of the Phase 3 TransportNPC study to meet primary efficacy endpoints.
  • Rafael Holdings shares dropped 34.98% on September 30, 2026, following the clinical trial announcement.

📝 Executive Summary

Pomerantz LLP has launched an investigation into Rafael Holdings, Inc. (RFL) regarding potential securities fraud. The probe follows the company's September 30, 2026, disclosure that its Phase 3 TransportNPC study failed to reach statistical significance, which triggered a 34.98% decline in the company's share price.

❓ FAQ

Why is Rafael Holdings under investigation?

The law firm Pomerantz is investigating whether Rafael and certain officers or directors engaged in securities fraud after the company's September 30, 2026, announcement that its Phase 3 TransportNPC study failed to achieve statistical significance.

How did the market react to the clinical trial news?

Rafael Holdings stock fell $0.71 per share, or 34.98%, to close at $1.32 per share on September 30, 2026, following the disclosure of the trial results.